Neurological diseases, including neurodegenerative and neurodevelopmental disorders, affect nearly one in six of the world’s population. The burden of the resulting deaths and disability is set to rise during the next few decades as a consequence of an aging population. To address this, zebrafish have become increasingly prominent as a model for studying human neurological diseases and exploring potential therapies. Zebrafish offer numerous benefits, such as genetic homology and brain similarities, complementing traditional mammalian models and serving as a valuable tool for genetic screening and drug discovery. In this comprehensive review, we highlight various drug delivery techniques and systems employed for therapeutic interventions of neurological diseases in zebrafish, and evaluate their suitability. We also discuss the challenges encountered during this process and present potential advancements in innovative techniques.

Sweet syndrome (SS) is an acute febrile neutrophilic dermatosis characterized by a constellation of clinical symptoms and histologic findings: pyrexia, neutrophilia, and tender and erythematous cutaneous lesions (plaques, nodules, and papules) with neutrophilic infiltration of the upper reticular dermis. SS can be either an inflammatory disease or a hypersensitivity disorder. SS has been associated with autoimmune disease, such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and sarcoidosis. We herein present a case of a 70‐year‐old white male presenting for persistent fevers, rash, intermittent diarrhea, and hematochezia. The patient had marked improvement of his clinical symptoms following systemic corticosteroid treatment. He was diagnosed with SS and ileocecal Crohn’s disease (CD). This article highlights the need to rule out CD in the setting of SS and gastrointestinal (GI) manifestations.

We present the case of a 39‐year‐old woman with a history of severe ulcerative colitis (UC) that was refractory to 5‐aminosalicylates, corticosteroids, and biologics, and who subsequently underwent total colectomy with ileal pouch–anal anastomosis (IPAA). She developed chronic antibiotic‐refractory pouchitis (CARP) characterized by recurrent abdominal pain, cramping, and diarrhea unresponsive to standard treatments. A comprehensive workup, including testing for anti‐tissue transglutaminase IgA antibodies, led to the diagnosis of de novo celiac disease, confirmed by endoscopic and histopathologic findings. Initiation of a gluten‐free diet resulted in the resolution of symptoms, with no relapse observed during a 9‐month follow‐up. Our case highlights the importance of considering secondary etiologies such as celiac disease in patients with chronic refractory pouchitis and emphasizes the need for tailored management strategies.

Introduction: Primary splenic angiosarcoma (PSA) is a rare type of angiosarcoma often associated with an unfavorable prognosis. The presenting symptoms are usually nonspecific, adding to the diagnostic difficulty of this disease. Limited cases have been described in younger adults, as most cases have been reported in individuals between 50 and 70 years old. Presentation of Case: We report the case of a 25‐year‐old patient with cerebral palsy who initially presented for high‐grade fever and left upper quadrant (LUQ) pain. On computed tomography (CT) scan, a large heterogenous mass was discovered in the spleen, and the patient underwent total splenectomy with pathological analysis confirming the diagnosis of PSA. The patient had no further complications and is still clinically stable. Discussion: PSA’s pathogenesis is not fully understood, though potential risk factors include exposure to chemicals or radiation, none of which were present in this case. Diagnosing PSA is challenging due to nonspecific symptoms and imaging findings that overlap with benign splenic lesions. Treatment primarily involves splenectomy, but prognosis remains poor due to the high likelihood of early metastasis. Adjuvant therapies, including chemotherapy and targeted agents, are under investigation. Conclusion: PSA is a rare and aggressive malignancy with significant diagnostic and therapeutic challenges. Early recognition and timely management may be important in selected cases, and outcomes remain poor, highlighting the need for further research to optimize treatment strategies.